Navigation Links
Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
Date:6/30/2009

GIA announces the release of a comprehensive global report on Small Molecule Kinase Inhibitors market. World market for small molecule kinase inhibitor drugs is projected to reach $16.2 billion by the year 2015. This is primarily driven by the rising interest over the potential of kinase inhibitors in effectively blocking, and modifying protein kinase triggered tumor cell metabolism, proliferation, and DNA damage. Strong growth in the future will be led by expansion of treatment indications in both oncology, and non-oncology disease areas.

San Jose, CA (PRWEB) June 30, 2009 -- With over 500 identified types of kinase proteins in the human body, its little surprise that these enzymes continue to remain important drug targets for major pharmaceutical drug developers, especially in the oncology space. Given their role in effectively disrupting cell signal pathways, kinase inhibitors are of special interest in the treatment of cancer. The unprecedented success witnessed in patient outcomes with the use of currently commercialized kinase inhibitors, such as, imatinib, among others, has ignited excitement over the untapped potential of this very potent class of drugs. Rising incidences of cancer, and the yet unmet treatment needs offer a strong business case for kinase inhibitors.    

The upcoming years are forecast to witness both the strong growth for multi-targeted kinase inhibitors, and the rising popularity of combination drug therapies. Growing incidences of tumor cell resistance to single targeted kinase inhibitor drugs is fingered as the key reason triggering interest in both combination drug therapies, and multi-targeted kinase inhibitors. For instance, growing incidences of resistance to Gleevec, has turned the spotlight on Nexavar, and Sutent, given the potential of these new drugs to offer the much awaited solution to the treatment impasse hitherto encountered. The multi-targeted kinase inhibitors market is expected to benefit from the growing acceptance of the undisputable fact that the battle against cancer can be horned not by blocking out tumor cells at one point, but by simultaneously blocking multiple biological triggers and pathways, given the tendency of these cells to regroup to recalibrate and spread through new growth paths.

Global sales of Gleevec are projected to steadily increase between the period 2010 and 2015, as stated by the new market research report. New generation kinase inhibitor drugs like Nexavar are forecast to witness robust growth over the period 2006 through 2015.

Leading players operating in the marketplace include Amgen Inc, Novartis, AstraZeneca plc, Genentech, Roche, OSI Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Glaxo SmithKline, Wyeth, Onyx Pharmaceuticals Inc., Merck & Co. Inc, KAI Pharmaceuticals Inc, Celgene Corporation, Sanofi-Aventis, and Bayer Schering Pharma AG, among others.

The report titled "Small Molecule Kinase Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of industry overview, technology, trends, growth drivers, challenges, and most promising drugs in pipeline. Also provided are profiles of major players, and an enumeration of recent developments, mergers, acquisitions, and other strategic industry activities. Global small molecule kinase inhibitors market is analyzed by sales in US$ billion of major drug brands, such as, Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, and Tykerb/Tyverb, among others.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/small_molecule/kinase_inhibitors/prweb2559784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
2. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
3. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
4. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
5. deCODE Reinstated to Nasdaq Global Market
6. BIO Ventures for Global Health Announces Management Changes
7. World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
8. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
9. Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels
10. BD and FIND Achieve Milestone in Global Battle Against MDR-TB
11. Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
(Date:1/18/2017)... , ... January 18, 2017 , ... ... and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff ... past year and is planned for further growth in 2017. Extractable & Leachable ...
(Date:1/18/2017)... IL (PRWEB) , ... January 18, 2017 , ... ... on January 24th, 2017, to sell research and genetic testing lab equipment from ... service in the Northwest and Northeast regions of the United States. This 1-day ...
(Date:1/18/2017)... , Jan. 18, 2017  Caris Life Sciences, ... Lustgarten Foundation, the largest private funder of pancreatic ... trial evaluating the impact of immunotherapy in the ... trial enrollment services to identify potential trial candidates ... between treating physicians and study investigators. The Lustgarten ...
(Date:1/17/2017)... 17, 2017 The Global Implantable Biomaterials ... of around 7.5% over the next decade to ... the prominent trends that the market is witnessing ... & graft transplant surgeries and medical implants and ... is categorized into immunomodulatory biomaterials, natural, polymers, hydrogels ...
Breaking Biology Technology:
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
Breaking Biology News(10 mins):